Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Endoxifen - Intas Pharmaceuticals/Jina pharmaceuticals

Drug Profile

Endoxifen - Intas Pharmaceuticals/Jina pharmaceuticals

Alternative Names: 4-Hydroxy-N-desmethyltamoxifen; Z-endoxifen; Z-Endoxifen Hydrochloride

Latest Information Update: 14 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Developer Intas Pharmaceuticals; Jina Pharmaceuticals; National Cancer Institute (USA)
  • Class Antineoplastics; Methylamines; Phenyl ethers; Stilbenes
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Bipolar disorders
  • Phase II Breast cancer
  • Phase I Fibroma; Gynaecological cancer

Most Recent Events

  • 30 Apr 2019 Intas Pharmaceuticals completes a phase III trial in Bipolar disorders in India (PO) (CTRI2017-07-009163)
  • 23 Apr 2019 National Cancer Institute suspends phase I trial in Breast cancer (Neoadjuvant therapy, Metastatic disease) in USA (Topical) (NCT03317405)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top